Vassilis Georgoulias

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 434 citations

Medicine, Oncology, Pharmacology +9

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

Galatea Kallergi, Maria A. Papadaki, Eleni Politaki et al. · Breast Cancer Research · 2011 · 373 citations · Full text

Medicine, Cell Biology, Oncology +17

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

Vassilis Georgoulias, E. Papadakis, A. Alexopoulos et al. · The Lancet · 2001 · 346 citations

Medicine, Oncology, Chemotherapy +12